Export 5 results:
Author Title Type [ Year(Asc)]
Filters: Author is Nakamura, Aya  [Clear All Filters]
2021
S. Sivapalasingam, Saviolakis, G. A., Kulcsar, K., Nakamura, A., Conrad, T., Hassanein, M., Sumner, G., Elango, C., Kamal, M. A., Eng, S., Kyratsous, C. A., Musser, B. J., Frieman, M., Kantrowitz, J., Weinreich, D. M., Yancopoulos, G., Stahl, N., and Lipsich, L., “Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).”, J Infect Dis, 2021.
F. Scaggs Huang, Bernstein, D. I., Slobod, K. S., Portner, A., Takimoto, T., Russell, C. J., Meagher, M., Jones, B. G., Sealy, R. E., Coleclough, C., Branum, K., Dickey, M., Buschle, K., McNeal, M., Makowski, M., Nakamura, A., and Hurwitz, J. L., “Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.”, Hum Vaccin Immunother, vol. 17, no. 2, pp. 554-559, 2021.
2020
L. Lai, Ault, K., Rouphael, N., Beck, A., Domjahn, B., Xu, Y., Anderson, E. J., Cheng, A., Nakamura, A., Hoagland, R. J., Kelley, C., Edupuganti, S., Mask, K., Nesin, M., Unger, E. R., Panicker, G., David, H., and Mulligan, M. J., “Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure.”, Vaccines (Basel), vol. 8, no. 3, 2020.
2018
L. E. Widdice, Hoagland, R., S Callahan, T., Kahn, J. A., Harrison, C. J., Pahud, B. A., Frey, S. E., Berry, A. A., Kotloff, K. L., Edwards, K. M., Mulligan, M. J., Sudman, J., Nakamura, A., and Bernstein, D. I., “Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series.”, Vaccine, vol. 36, no. 11, pp. 1491-1499, 2018.
L. A. Jackson, Sahly, H. M. El, George, S., Winokur, P., Edwards, K., Brady, R. C., Rouphael, N., Keitel, W. A., Mulligan, M. J., Burton, R. L., Nakamura, A., Ferreria, J., and Nahm, M. H., “Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.”, Vaccine, vol. 36, no. 5, pp. 606-614, 2018.